70% of Women Under 50 Diagnosed With Mesothelioma Have a Family Cancer History. BAP1 Syndrome Is Now the Lens.

Mesothelioma has been understood, for half a century, as an occupational disease. Workers exposed to asbestos in their jobs developed it 20 to 50 years later. The classic patient was male, in his sixties or seventies, with a documented work history involving asbestos.

That model is incomplete. Memorial Sloan Kettering Cancer Center published a study in JCO Precision Oncology in March 2026 documenting a cohort that doesn’t fit the model: women under 50, with no significant occupational asbestos exposure, diagnosed with mesothelioma at a stage of life when the disease has traditionally been rare. The study reported that 70% of those women had a family history of breast, lung, or colon cancer.

The lens for understanding this cohort is BAP1 tumor predisposition syndrome. It’s a real genetic syndrome with a real clinical surveillance protocol and active NCI clinical trials testing prevention strategies. This is what the field now knows about it and what it means for families with cancer histories.

What the MSKCC Study Found

Memorial Sloan Kettering’s March 2026 publication in JCO Precision Oncology centered on the family cancer history pattern in young women diagnosed with mesothelioma. The 70% figure, the proportion of women under 50 with mesothelioma who had a family history of breast, lung, or colon cancer, is the headline number. It’s a substantially elevated rate compared to the general population and points toward a genetic explanation for the cohort.

The study advances the case for routine germline genetic testing in young people with mesothelioma, particularly women. It also supports cancer screening of first-degree relatives in families that match the BAP1-TPDS pattern. See the MSKCC younger-patients BAP1 coverage for the broader study context.

The implication for clinical practice is concrete. A 42-year-old woman with peritoneal mesothelioma, no documented asbestos exposure, and a mother who died of breast cancer and an aunt who died of melanoma is now a candidate for germline BAP1 testing in the routine work-up of her diagnosis. A positive result changes care for her and creates a surveillance recommendation for her siblings, her children, and other first-degree relatives.

What BAP1 Is and What It Does

BAP1 (BRCA1-associated protein 1) is a tumor suppressor gene located on chromosome 3p21. The gene encodes a deubiquitinating enzyme that regulates chromatin and participates in DNA damage repair. When BAP1 function is lost, cells lose a key check on uncontrolled growth, which is the mechanism by which BAP1 mutations contribute to cancer.

BAP1 loss occurs through two distinct pathways. Germline BAP1 mutations are inherited; every cell in the body carries the mutation. Somatic BAP1 mutations occur during life in specific cells, typically in a tumor itself, without affecting the rest of the body. Both pathways are clinically important in mesothelioma. Approximately 60% of pleural mesothelioma tumors show somatic BAP1 loss in tissue, separate from the patient’s germline status. The somatic BAP1 loss in tumor tissue has prognostic and therapeutic implications regardless of whether the patient has BAP1-TPDS.

The syndrome (BAP1-TPDS) is the germline form. Carriers have one functional copy of BAP1 in every cell and one mutated copy. When the functional copy is lost in a specific cell, typically through a “second hit” somatic mutation, that cell loses BAP1 function entirely and can develop into a cancer. The syndrome’s hallmark cancers, mesothelioma, uveal melanoma, cutaneous melanoma, renal cell carcinoma, basal cell carcinoma, all show this pattern.

See the BAP1 gene mutation mesothelioma background and the BAP1 mesothelioma mechanisms and clinical opportunities coverage for the underlying science.

How BAP1-TPDS Mesothelioma Differs from Sporadic Disease

The clinical picture of BAP1-TPDS mesothelioma is meaningfully different from sporadic asbestos-driven disease.

Age at diagnosis. BAP1-TPDS mesothelioma can develop at substantially younger ages than the typical sporadic case. The MSKCC study’s focus on women under 50 reflects this pattern.

Site of disease. BAP1-TPDS mesotheliomas are more often peritoneal than pleural. Sporadic asbestos-driven mesothelioma in male occupational cohorts is predominantly pleural. The site difference reflects the underlying mechanism: occupational asbestos exposure primarily reaches the pleura through inhalation, while BAP1-driven mesothelioma develops based on the genetic vulnerability of mesothelial cells in either site.

Survival. BAP1 carriers show approximately 7-fold increased long-term survival compared to sporadic mesothelioma cases. This is one of the most significant clinical findings in the BAP1-TPDS literature. The mechanism is not fully understood, but the consistency of the observation across multiple cohorts has made it a defining feature of the syndrome.

Exposure history. Many people with BAP1-TPDS mesothelioma have minimal or no documented occupational asbestos exposure. This contrasts sharply with the sporadic disease pattern. The MSKCC study’s emphasis on the absence of significant asbestos exposure in many of the young-female cases is consistent with this pattern.

The clinical implications run in both directions. A patient with sporadic, asbestos-driven, pleural mesothelioma typically has a more challenging prognosis. A patient with BAP1-TPDS mesothelioma, even with the same disease stage at diagnosis, typically has a more favorable long-term trajectory. The two paths converge in current treatment options: surgery for resectable disease, chemoimmunotherapy, immunotherapy as first-line for unresectable disease, and clinical trials when standard options are exhausted.

The Carbone Lab Registry and BAP1 Discovery

The clinical identification of BAP1-TPDS as a distinct syndrome traces in significant part to Michele Carbone’s lab at the University of Hawaii Cancer Center. The Carbone Lab identified germline BAP1 mutations in mesothelioma families in the early 2010s, leading to the recognition of BAP1 as a hereditary mesothelioma risk factor. The lab maintains a familial mesothelioma registry that tracks BAP1-TPDS families and supports research enrollment.

See the Michele Carbone BAP1 and LBAM discovery coverage for the discovery narrative.

The 181 BAP1-mutation families identified worldwide through 2023 (per the Walpole and colleagues compilation) are the documented baseline. The true population prevalence is unknown because most cancer-prone families have not been tested. As germline testing becomes more routine in people diagnosed with mesothelioma, particularly young people and those with strong family cancer histories, the count will grow.

What the NCI Trials Are Testing

Two NCI clinical trials are actively testing intervention approaches for BAP1-TPDS mesothelioma.

NCT05960773 is testing oral epigenetic agents for prevention of BAP1-syndrome mesothelioma progression. The trial enrolls BAP1 carriers with documented disease and tests whether epigenetic interventions can slow or prevent disease advancement.

NCT06654050 is testing additional intervention approaches for BAP1-syndrome mesothelioma. The specific intervention protocol and primary endpoint are documented in the ClinicalTrials.gov registration.

Both trials operate in a population that is identifiable through germline testing. The increasing availability of clinical BAP1 testing creates a pipeline of potential trial enrollees. For BAP1 carriers and their families, the trials represent a path toward intervention that didn’t exist a decade ago.

What the Price and Pickett 2024 Review Adds

The 2024 review by Price and Pickett (PMC11626854) of approximately 200 US studies of female mesothelioma found that female mesothelioma incidence rates have remained relatively stable for 50 years despite documented declines in occupational asbestos exposure. The review noted that post-1973 exposures should have produced a measurable decline in female mesothelioma incidence by 2018 based on the latency window. That decline has not appeared in the data.

The review attributes the stability of female mesothelioma incidence to non-asbestos factors, including genetic factors. The MSKCC March 2026 study’s finding of high family cancer history in young female cases is consistent with the Price and Pickett analysis: if a significant share of female mesothelioma cases derive from BAP1-TPDS or other genetic mechanisms rather than from occupational asbestos exposure, the historical decline in occupational exposure would not produce a corresponding decline in female incidence.

See the mesothelioma in women coverage for the broader demographic and clinical picture of female mesothelioma.

What This Means for Families With Cancer Histories

The practical implications for families with cancer histories are concrete.

If a person has a personal or family history that includes mesothelioma (especially at younger ages), uveal melanoma, cutaneous melanoma, renal cell carcinoma, basal cell carcinoma, or combinations of these cancers across close relatives, BAP1-TPDS is on the differential. A clinical geneticist or genetic counselor can assess whether the family history pattern meets criteria for germline BAP1 testing.

If germline testing identifies a pathogenic BAP1 variant in one family member, first-degree relatives (siblings, children, parents) are 50% likely to carry the same variant. Cascade testing of those relatives can identify additional carriers who would benefit from surveillance.

Surveillance for BAP1-TPDS carriers typically includes dermatologic examination for cutaneous melanoma and basal cell carcinoma, ophthalmologic examination for uveal melanoma, renal imaging for renal cell carcinoma, and clinical follow-up for the early symptoms of mesothelioma. Specific NCCN screening recommendations for BAP1-TPDS carriers exist and should be discussed with a clinical geneticist familiar with the syndrome’s current guidelines.

For a person already diagnosed with mesothelioma, germline BAP1 testing is increasingly part of the routine work-up. A positive result has prognostic implications, may affect treatment decisions including clinical trial eligibility, and creates the surveillance recommendation for first-degree relatives.

What This Doesn’t Mean

A few things the BAP1 story doesn’t change.

It doesn’t change the fact that asbestos exposure is the dominant cause of mesothelioma in the US population overall, particularly in male occupational cohorts. The asbestos-driven cases continue to make up the substantial majority of mesothelioma diagnoses.

It doesn’t change the legal options for people with asbestos-driven mesothelioma. Trust fund claims, civil litigation, and VCF claims for 9/11 first responders all continue to operate on the same framework regardless of any underlying genetic component. See the mesothelioma legal options guide for the full framework. BAP1 carriers exposed to asbestos may have a compounded risk picture but their legal options for asbestos exposure remain available.

It doesn’t change the recommendation that family members of asbestos-exposed workers minimize secondary exposure. The genetic component does not eliminate the environmental component; the two can compound.

What the BAP1 story does change is the framework for understanding why young women, without significant asbestos exposure, sometimes develop a disease that has historically been associated with industrial work histories. The MSKCC March 2026 study moves that framework from the research literature into the clinical care decision space. Families with the right cancer history pattern now have a defined path: genetic counseling, testing, surveillance for carriers, and access to clinical trials for those with the syndrome.

For people facing those decisions, the next steps are with a clinical geneticist or genetic counselor. The science continues to develop. The clinical care framework is now in place.